- Home
- CABA vs USDE Comparison
CABA vs USDE Comparison
Compare CABA & USDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CABA | USDE |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.1M | 296.0M |
| IPO Year | 2019 | 2026 |
Fundamental Metrics
Financial Performance| Metric | CABA | USDE |
|---|---|---|
| Price | $1.42 | $10.71 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $13.25 | N/A |
| AVG Volume (30 Days) | ★ 5.3M | 3.4M |
| Earning Date | 11-09-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.26 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.51 | $1.33 |
| 52 Week High | $4.23 | $17.50 |
Technical Indicators
Market Signals| Indicator | CABA | USDE |
|---|---|---|
| Relative Strength Index (RSI) | 20.85 | 46.15 |
| Support Level | N/A | $5.87 |
| Resistance Level | $2.14 | $17.50 |
| Average True Range (ATR) | 0.14 | 1.23 |
| MACD | -0.03 | -0.71 |
| Stochastic Oscillator | 4.74 | 4.13 |
Price Performance
Historical ComparisonAbout CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
About USDE StablecoinX Inc. Class A Common Stock
StableCoinX Inc is a newly-formed validator and infrastructure business expected to operate infrastructure and staking services, running validators and related technical services for the Ethena protocol. The company is expected to adopt a multi-year treasury strategy to build a reserve of ENA, the Ethena protocol's native token.